NCT07098091View on ClinicalTrials.gov

Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of YD0293 in Healthy Subjects

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

February 26, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Healthy Participants
Interventions
DRUG

YD0293

YD0293 tablet for oral administration

DRUG

YD0293 placebo

YD0293 placebo tablet for oral administration

Trial Locations (1)

Unknown

The Second Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.

INDUSTRY